An Open-Label, Randomized, Active Controlled Inpatient Trial Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Dexmedetomidine (Primary) ; Lorazepam (Primary)
- Indications Agitation
- Focus Therapeutic Use
- 26 Oct 2023 New trial record